Slideshow

Gout: 3 New Things

Author(s):

The gout-dementia connection, daily medication reminders, and the impact of interleukin-1β inhibition on gout attacks.

References1. Singh JA, Cleveland JD. Gout and dementia in the elderly: a Medicare claims study. Ann Rheum Dis. 2018;77:140. Abstract OP0182.2. Bunphong K, Narongroeknawin P. Mobile phone text messages for improving allopurinol adherence: a randomised controlled trial of text message reminders. Ann Rheum Dis. 2018;77:155. Abstract OP0212.3. Solomon D, Glynn RJ, MacFadyen JG, et al. Serum urate, gout, and cardiovascular disease in a randomised controlled trial of canakinumab: a CANTOS secondary analysis. Ann Rheum Dis. 2018;77:56-57. Abstract OP0014.

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
© 2024 MJH Life Sciences

All rights reserved.